A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant

Patients in need of an allogeneic hematopoietic cell transplant (HCT) are at risk of developing graft-versus-host-disease (GVHD). In certain clinical situations, the optimal approach to minimize the risk of GVHD is to perform ex vivo alpha-beta T-cell depletion of the donor cells. However, the CliniMACS® Device is FDA-approved only for a narrow indication. All other uses of ex vivo processed cells must be done under a feasibility study protocol.

Sponsor

Christopher Dvorak

Status of enrollment

Accepting new patients

Ages Eligible for Study

For people up to age 30

Disease indication

Graft Vs Host Disease, Bone Marrow Transplant, Transplants

Principal Investigator

Chris Dvorak, MD

Contact

Kenny Truong, RN, BSN: [email protected]

 

Additional study eligibility details can be found at UCSF Clinical Trials.